Literature DB >> 19758635

Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.

Amy S Duffield1, Thomas K Lee, Hiroshi Miyamoto, H Ballantine Carter, Jonathan I Epstein.   

Abstract

PURPOSE: Little data are available on radical prostatectomy findings in men who experience disease progression following active surveillance.
MATERIALS AND METHODS: A total of 470 men in our active surveillance program underwent annual repeat needle biopsies to look for progression defined as any Gleason pattern grade 4/5, more than 50% cancer on any core or cancer in more than 2 cores. Slides were available for review in 48 of 51 radical prostatectomies with progression.
RESULTS: The average time between the first prostate biopsy and radical prostatectomy was 29.5 months (range 13 to 70), with 44% and 75% of the patients showing progression by the second and third biopsy, respectively. There were 31 (65%) organ confined cases, of which 25 (52%) were Gleason score 6. Of 48 cases 17 (35%) had extraprostatic extension, 3 had seminal vesicle/lymph node involvement and 7 (15%) had positive margins. Mean total tumor volume was 1.3 cm(3) (range 0.02 to 10.8). Of the 48 tumors 13 (27%) were potentially clinically insignificant (organ confined, dominant nodule less than 0.5 cm(3), no Gleason pattern 4/5) and 19% (5 of 26) of the radical prostatectomies with a dominant tumor nodule less than 0.5 cm(3) demonstrated extraprostatic extension, 4 with Gleason pattern 4. All 10 tumors with a dominant nodule greater than 1 cm(3) were located predominantly anteriorly.
CONCLUSIONS: Most progression after active surveillance occurs 1 to 2 years after diagnosis suggesting undersampling of more aggressive tumor rather than progression of indolent tumor. Even with progression most tumors have favorable pathology (27% potentially insignificant). A small percentage of men have advanced stage disease (pT3b or N1). The anterior region should be sampled in men on active surveillance.

Entities:  

Mesh:

Year:  2009        PMID: 19758635      PMCID: PMC4390036          DOI: 10.1016/j.juro.2009.07.024

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection.

Authors:  Masami Watanabe; Toshihide Hayashi; Tomoyasu Tsushima; Shin Irie; Tetsuzo Kaneshige; Hiromi Kumon
Journal:  Int J Urol       Date:  2005-11       Impact factor: 3.369

2.  Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer.

Authors:  J I Epstein; P C Walsh; J Sauvageot; H B Carter
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

3.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Authors:  H Ballentine Carter; Patrick C Walsh; Patricia Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

4.  Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology.

Authors:  Sébastien Bouyé; Eric Potiron; Philippe Puech; Xavier Leroy; Laurent Lemaitre; Arnauld Villers
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

5.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.

Authors:  Masanori Noguchi; Thomas A Stamey; John E McNeal; Rosalie Nolley
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

7.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

8.  Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.

Authors:  Ghil Suk Yoon; Wenle Wang; Adeboye O Osunkoya; Zhaoli Lane; Alan W Partin; Jonathan I Epstein
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

9.  Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.

Authors:  Hikmat A Al-Ahmadie; Satish K Tickoo; Semra Olgac; Anuradha Gopalan; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

10.  Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.

Authors:  Ahmed Magheli; Soroush Rais-Bahrami; Hugh J Peck; Patrick C Walsh; Jonathan I Epstein; Bruce J Trock; Mark L Gonzalgo
Journal:  J Urol       Date:  2007-08-16       Impact factor: 7.450

View more
  26 in total

1.  [Diagnostics and therapy of localized prostate cancer: a problem-oriented account].

Authors:  C Weber
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

2.  Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.

Authors:  Satheesh Krishna; Nicola Schieda; Matthew Df McInnes; Trevor A Flood; Rebecca E Thornhill
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

Review 3.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 4.  Interventional therapy in malignant conditions of the prostate.

Authors:  Attila Kovács; Michael Pinkawa
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

5.  Role of active surveillance in the management of localized prostate cancer.

Authors:  Allison S Glass; Matthew R Cooperberg; Maxwell V Meng; Peter R Carroll
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland.

Authors:  J C Forde; P J Daly; S White; M Morrin; G P Smyth; B D P O'Neill; R E Power
Journal:  Ir J Med Sci       Date:  2013-09-29       Impact factor: 1.568

Review 7.  Active surveillance in men with low-risk prostate cancer: current and future challenges.

Authors:  Christopher Sejong Han; Jaspreet Singh Parihar; Isaac Yi Kim
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

8.  Correlation of magnetic resonance imaging tumor volume with histopathology.

Authors:  Baris Turkbey; Haresh Mani; Omer Aras; Ardeshir R Rastinehad; Vijay Shah; Marcelino Bernardo; Thomas Pohida; Dagane Daar; Compton Benjamin; Yolanda L McKinney; W Marston Linehan; Bradford J Wood; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

9.  Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.

Authors:  Robert R Flavell; Antonio C Westphalen; Carmin Liang; Christopher C Sotto; Susan M Noworolski; Daniel B Vigneron; Zhen J Wang; John Kurhanewicz
Journal:  Abdom Imaging       Date:  2014-10

10.  Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.

Authors:  Jeong S Han; Adam D Toll; Ali Amin; H Ballentine Carter; Patricia Landis; Stephen Lee; Jonathan I Epstein
Journal:  Urology       Date:  2012-08-22       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.